Reduction of dopamine release and synthesis by repeated amphetamine treatment: role in behavioral sensitization

European Journal of Pharmacology
A ImperatoG L Gessa

Abstract

Changes in extracellular dopamine concentration in the ventral striatum during repeated amphetamine administration and over the first 7 days of withdrawal were studied by transversal microdialysis in freely moving rats. 2 days after fiber implantation rats were treated with either amphetamine (1.5 mg/kg i.p.) or saline every 12 h for 14 days. In amphetamine-treated rats, the baseline extracellular dopamine concentration, preceding the morning treatment, increased from 0.43 +/- 0.01 on day 1 up to 0.59 +/- 0.02 pmol/40 microliters sample on day 3 of treatment. Thereafter, dopamine fell rapidly on day 5(0.16 +/- 0.01 pmol/40 microliters) and remained at approximately the level reached on day 7(0.11 +/- 0.01 pmol/40 microliters) throughout the treatment and also over the 7 days of withdrawal. In contrast, in control rats, the extracellular dopamine concentration (0.40 +/- 0.01 pmol/40 microliters, on day 1) decreased progressively during the first days of treatment to reach a fairly stable value on day 4 (0.25 +/- 0.01 pmol/40 microliters sample). Thereafter, dopamine remained stable at this level throughout the remaining period of experimentation. Challenge with amphetamine (1.5 mg/kg i.p.) of animals treated with amphetamine for...Continue Reading

References

Jan 1, 1976·Psychopharmacologia·N J Leith, R J Barrett
Jul 1, 1992·Psychiatry Research·C J McDougleH D Kleber
Mar 3, 1992·European Journal of Pharmacology·A ImperatoS Puglisi-Allegra
Jan 25, 1991·European Journal of Pharmacology·E AcquasG Di Chiara
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Di Chiara, A Imperato
Mar 1, 1994·Pharmacology, Biochemistry, and Behavior·G R KingE H Ellinwood
Sep 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·M DianaZ L Rossetti
Jan 1, 1993·Behavioural Pharmacology·P. WillnerM. Emmett-Oglesby
Jan 1, 1993·Behavioural Pharmacology·J. Stewart, A. Badiani
Jan 1, 1993·Behavioural Pharmacology·P.W. KalivasM.S. Hooks

❮ Previous
Next ❯

Citations

Aug 6, 1999·Biological Psychiatry·R R GainetdinovM G Caron
Jan 25, 2003·Pharmacology, Biochemistry, and Behavior·Nicole M Avena, Bartley G Hoebel
Sep 22, 2001·Neuroscience and Biobehavioral Reviews·N M RichtandS M Strakowski
May 20, 2003·Neurotoxicity Research·Barbara K. Lipska, Daniel R. Weinberger
Mar 1, 2009·Journal of Addiction Medicine·Bartley G HoebelPedro Rada
Dec 17, 2003·Biological Psychiatry·Cindy L BrandonFrancis J White
May 10, 2011·Physiology & Behavior·Erin N Umberg, Emmanuel N Pothos
Jul 31, 2003·The European Journal of Neuroscience·Barbara K LipskaDaniel R Weinberger
Dec 23, 2008·Behavioural Brain Research·Kuei Y TsengBarbara K Lipska
May 1, 2012·Journal of Clinical Psychopharmacology·Erin N UmbergDavid J Greenblatt
May 12, 2006·Critical Reviews in Toxicology·E Mariussen, F Fonnum
Nov 21, 2000·Annals of the New York Academy of Sciences·R B RothmanM H Baumann
Oct 14, 2018·Translational Psychiatry·Gitalee SarkerDaria Peleg-Raibstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.